Mar 26,2020

NHS staff across England get free access to mental health apps Daylight and Sleepio

NHS England has announced a national mental health support programme to provide NHS staff with evidence-based digital programmes to protect their mental health during the COVID-19 response. The NHS-accredited apps Daylight – designed to help with worry and anxiety – and Sleepio – a digital sleep improvement programme featuring Cognitive Behavioural Therapy (CBT) techniques – are both developed by digital therapeutics company Big Health. Fifteen NHS trusts and six GP practices have already rolled out access to the programmes to over 100,000 staff, with the apps now made freely available to all NHS employees across the country in partnership with NHS England.

COLLABORATION PARTNERSHIP

#institution

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Mar 26,2020

Pear Therapeutics Obtains FDA Authorization For Somryst, A Prescription Digital Therapeutic For The Treatment Of Adults With Chronic Insomnia

Pear Therapeutics, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted authorization for Somryst™, the first prescription digital therapeutic (PDT) intended for use in the treatment of patients 22 years of age and older with chronic insomnia. Somryst treats patients with chronic insomnia by improving a patient’s insomnia symptoms, and it is the first product submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed as part of FDA’s Software Precertification Pilot Program to help build and test FDA’s Digital Health Precertification Working Model 1.0.

REGULATORY FDA

#cbt

#pdt

View Analyst & Ambassador Comments
Go to original news
Mar 27,2020

Happify Health Offers Free Resources to Help People Manage Stress and Worry During Global Pandemic

Today, leading digital mental health company, Happify Health, announced the availability of a variety of free resources to help people manage stress and worry amidst the COVID-19 pandemic, including exclusive new content tracks, a webinar to help juggle work and homelife responsibilities, weekly yoga via Facebook Live, self-help articles with insights from experts, and more. Three tracks of specially curated content will be accessible to everyone at no cost by visiting together.happify.com. The first, “Managing Stress in Uncertain Times,” is a brand new content track specifically designed to address the challenges people are facing as a result of our current global crisis.

PRODUCT

#cbt

View Analyst & Ambassador Comments
Go to original news
Apr 15,2020

Sentio Solutions Launches Feel Relief Program to Support Mental Health During COVID-19

To meet the growing demand and need for mental health support during the ongoing COVID-19 pandemic, Feel Therapeutics (formerly Sentio Solutions) is launching the Feel Relief Program which will be available to anyone experiencing increased stress or uncertainty. The Feel Relief Program is a four-week, fully remote mental health support program. The program includes access to mental health resources, an app to journal emotions and complete mental health exercises, as well as weekly online 15-minute sessions with coaches.

PRODUCT

#cbt

#coaching

View Analyst & Ambassador Comments
Go to original news
Apr 29,2020

Pear Therapeutics To Release Pear-004 To Help People Living With Schizophrenia During The Covid-19 Crisis

Pear Therapeutics, Inc., the leader in prescription digital therapeutics (PDTs), today announced that it is launching a limited distribution program for its product candidate, Pear-004, for people living with schizophrenia. Based on FDA’s Enforcement Policy for Digital Health Devices for Treating Psychiatric Disorders During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency, Pear plans to provide patients with access to Pear-004 through collaborations with select healthcare providers and academic centers. Unlike Pear’s FDA-authorized products, reSET®, reSET-O®, and Somryst™, Pear-004 has not received market authorization from FDA.

PRODUCT

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
May 06,2020

Pear Therapeutics Launches Pear Assistance Program To Ensure Access To Prescription Digital Therapeutics, Reset® And Reset-O®, For People Living With Addiction

Pear Therapeutics, Inc. today announced the launch of the PEAR Assistance Program to ensure eligible patients living with Substance Use Disorder or Opioid Use Disorder have access to FDA-authorized prescription digital therapeutics (PDTs) for addiction treatment. The program will provide access to reSET® and reSET-0®, free of charge, to qualifying patients who are currently under the supervision of a licensed US healthcare provider.

PRODUCT

#cbt

#pdt

View Analyst & Ambassador Comments
Go to original news
Jun 10,2020

Digital Mental Health support to be Provided to Young People as they Return to School

SilverCloud, the leading digital therapeutics provider, has partnered with mental health charity Northpoint Wellbeing to co-develop a new digital therapy programme to alleviate anxiety in young people. Coming at a time when children are returning to school and face huge uncertainty, it will be available for school clusters across the Leeds area and NHS Child and Adolescent Services Mental Health Services (CAMHS) in Calderdale. The programme is also being rolled out nationally to other NHS and education services. The online treatment, based on cognitive behavioural therapy, is designed for young people 14 years and over but can be used for younger children if a professional assesses them as suitable.

COLLABORATION PARTNERSHIP

#r&d

#cbt

View Analyst & Ambassador Comments
Go to original news
Jul 20,2020

Meaningful digital health engagement is more complicated than how long or often users log in

Sustained engagement is a key metric when determining whether a digital health-based intervention is finding its mark, but the industry has been anything but uniform in determining objective measures of user behavior and their relationship to clinical outcomes. A study published Friday in JAMA Network Open takes another approach and employs machine learning techniques to better describe engagement among 54,604 patients provided a digital health intervention – in this case, an internet-based cognitive behavioral therapy (iCBT) tool for depression and anxiety symptoms developed by SilverCloud Health.

CLINICAL STUDY

#cbt

View Analyst & Ambassador Comments
Go to original news
Jul 29,2020

CVS Health Adds Big Health’s Digital Therapeutics for the 24-Hour Problem of Mental Health to Its Point Solutions Management Program

Big Health, the global leader in digital therapeutics dedicated to helping millions back to good mental health, today announced that its Daylight digital therapeutic for worry and anxiety is now available to employers and other plan sponsors through CVS Caremark’s Point Solutions Management program. Together, Sleepio and Daylight address the 24-hour problem of mental health, spanning poor sleep, worry and anxiety, with clinically proven, instantly accessible digital therapeutics. Point Solutions Management is a full-service offering that leverages the CVS Caremark PBM infrastructure to enable plan sponsors to more efficiently administer apps, online trackers and other digital point solutions that support their members’ health and well-being.

COLLABORATION PARTNERSHIP

#institution

#cbt

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 29,2020

Landmark Randomized Controlled Trial Demonstrates Efficacy of Daylight™ Digital Therapeutic in Improving Anxiety

The University of Oxford’s Sleep & Circadian Neuroscience Institute, and Big Health, today announced publication of a randomized controlled trial (RCT) assessing the efficacy and safety of Big Health’s Daylight product in improving symptoms of Generalized Anxiety Disorder (GAD), in the journal Depression and Anxiety. The study found that Daylight significantly reduced symptoms of anxiety in trial participants, as compared to the control group at six weeks after intervention. By week 10 follow-up, 71% of Daylight users in the study achieved remission of GAD, as compared to 33% of those in the control group.

CLINICAL STUDY

#cbt

View Analyst & Ambassador Comments
Go to original news
Subscribe to CBT